I Molnar
Overview
Explore the profile of I Molnar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Biau J, Durando X, Boux F, Molnar I, Moreau J, Leyrat B, et al.
Clin Transl Radiat Oncol
. 2024 Aug;
48:100833.
PMID: 39184998
Background: In glioblastoma (GBM), tumor progression occurs mainly within the irradiated tumor volume. To address this challenge, a radiosensitization strategy with intravenous gadolinium-based theranostic nanoparticles (AGuIX) is being explored in...
2.
Montoriol P, Hordonneau C, Boudinaud C, Molnar I, Abrial C, Kossai M
Clin Radiol
. 2021 May;
76(8):593-598.
PMID: 33933275
Aim: To evaluate the computed tomography (CT) and magnetic resonance imaging (MRI) features of benign Brenner tumours (BBT) of the ovary. Material And Methods: This was a retrospective two-centre study...
3.
Cabanie C, Biau J, Durando X, Mansard S, Molnar I, Chassin V, et al.
Cancer Radiother
. 2021 Apr;
25(5):432-440.
PMID: 33836954
Purpose: Stereotactic radiotherapy (SRT) is the standard treatment for brain metastases of non-small-cell lung cancer (NSCLC) and melanoma, mostly in combination with immunotherapy. The objective was to retrospectively evaluate the...
4.
Biau J, Thivat E, Chautard E, Stefan D, Boone M, Chauffert B, et al.
Radiother Oncol
. 2020 Sep;
154:227-234.
PMID: 32976869
Background And Purpose: This phase 1 trial aimed to determine the maximum tolerated dose (MTD; primary objective) of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the...
5.
Zoldhegyi A, Rieger H, Molnar I, Fekhretdinova L
J Pharm Biomed Anal
. 2018 May;
156:379-388.
PMID: 29783113
Human mistakes are still one of the main reasons of underlying regulatory affairs that in a compliance with FDA's Data Integrity and Analytical Quality by Design (AQbD) must be eliminated....
6.
Adiwijaya B, Kim J, Lang I, Csoszi T, Cubillo A, Chen J, et al.
Clin Pharmacol Ther
. 2017 Apr;
102(6):997-1005.
PMID: 28445610
Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t ), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (C ) compared with nonliposomal...
7.
Farkas I, Molnar I, Somlyay I, Toth E
Commun Agric Appl Biol Sci
. 2016 May;
80(2):149-52.
PMID: 27145579
The increasing pressure of oilseed rape pests emphasized the need to improve the insecticide portfolio, i.e. register new active ingredients with new insecticide mode of action. The tested seed treatment...
8.
Bardi G, Molnar I, Somlyay I, Toth E, Novak R, Hornyak A, et al.
Commun Agric Appl Biol Sci
. 2015 Jun;
79(2):97-8.
PMID: 26084086
No abstract available.
9.
10.
Molnar I, Bohaty I, Somogyine-Vari E
Osteoporos Int
. 2013 Dec;
25(2):783-6.
PMID: 24337660
Unlabelled: The role of proinflammatory IL-17 cytokine was studied in postmenopausal bone loss between 31 osteopenic and 41 osteoporotic women. The effect of serum IL-17A, soluble receptor activator of NF-κB...